The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants  by Murphy, Nicholas M. et al.
From the 1
of Ph
Austr
vice, A
3Depa
plant
4Depa
Wood
tology
Medic
Amste
plant
Austr
Unive
Financial d
Correspon
Depa
Pharm
Austr
Received J
 2012 A
Published
1083-8791
doi:10.101
722The Effect of Folinic Acid onMethylenetetrahydrofolate
Reductase Polymorphisms in Methotrexate-Treated
Allogeneic Hematopoietic Stem Cell Transplants
Nicholas M. Murphy,1 Mary Diviney,2 Jeff Szer,3 Peter Bardy,4 Andrew Grigg,5
Rosemary Hoyt,5 Belinda King-Kallimanis,6 Rhonda Holdsworth,7
James McCluskey,8 Brian D. Tait2,7This study examined the contribution single nucleotide polymorphisms (SNPs) of the 5,10-
methylenetetrahydrofolate reductase (MTHFR) gene have on clinical outcomes in hematopoietic stem cell
transplant patients treated with the antiproliferative drug methotrexate. Two common SNPs, 677C.T
and 1298A.C, were genotyped by polymerase chain reaction-restriction fragment-length polymorphism
(PCR-RFLP) from samples obtained from patient DNA samples. Eleven clinical outcomes including survival
and graft-versus-host disease (GVHD) were assessed against donor and recipient MTHFR genotypes against
pretransplantation variables. Folinic acid (FA) as treatment for oral mucositis toxicity was used at investigator
discretion in 72 of 140. DonorMTHFR 1298AA genotype was associated with decreased 5-year survival (P5
.03) and event-free survival (EFS) (P5 .02) in patients withheld FA. Donor MTHFR 677CC genotype was as-
sociated with earlier GVHD (P5 .003), and more severe acute GVHD (P5 0.02). FA was significantly asso-
ciated with decreased survival (P 5 0.02) in patients given a donor MTHFR 677CT transplant. FA was
significantly associated with decreased survival (P 5 .04), EFS (P 5 .009) in patients given a donor MTHFR
1298AC transplantMTHFR gene polymorphisms indicate a potentially useful gene for donor selection where
more than one donor is available. Use of FA following transplantation should be reconsidered in the context
of patient and donor MTHFR genotypes.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is a life-saving treatment for acquired and
congenital hematologic and immunologic conditions
[1,2]. Successful HSCT results in engraftment of the
recipient with healthy stem cells and induces a donor
T-lymphocyte mediated graft-versus-tumor (GVT)
response, useful in the treatment of malignant disease
and adding to the elimination of residual neoplastic
cells after chemotherapy and thereby reducing the
risk of relapse ofmalignancy [3]. Graft-versus-host dis-
ease (GVHD) is an unintended consequence of this T
cell response, which is frequently life threatening and
sometimes fatal. Simultaneously maximizing GVT
while minimizing GVHD is a major aim of HSCT
research. In the days following transplantation,
patients are routinely given doses of methotrexate
(MTX), an antiproliferative drug, as prophylaxis for
acute GVHD (aGVHD). This agent simultaneously
suppresses clonal T cell activation and expansion and
in some circumstances may also provide value as an
Biol Blood Marrow Transplant 18:722-730, 2012 723Effect of Folinic Acid on MTHFRantineoplastic [4]. However, as MTX contributes to
a variety of toxicities, dosage must be carefully evalu-
ated [5]. Patients are frequently ‘‘rescued’’ from MTX
toxicities, such as oropharyngealmucositis, with folinic
acid (FA) [6].
We previously linked the HSCT donor genotype
5,10-methylenetetrahydrofolate reductase (MTHFR)
677CC to the incidence and severity of GVHD [7].
This present study focused on the association of the
677C.T single nucleotide polymorphism (SNP) and
the adenine to cytosine mutation, 1298A.C, with the
clinical outcomes of HSCT. The function of the
MTHFR 1298C mutation has been shown to have
similar properties in terms of thermolability and flavin
adenine dinucleotide (FAD; a common biologic cofac-
tor) cofactor binding affinity as the MTHFR 1298A
wild type; however, the effect of the 1298C SNP on
S-adenosylmethionine (SAM) binding remains un-
clear. Here we explore the relationship between the
genotypes of MTHFR 677 and 1298 polymorphisms,
and assess associations to GVHD, event-free survival
(EFS), and survival. As the clinical impact of FA and
MTHFR has yet to be examined, we assessed the effect
that MTHFR SNPs had in influencing clinical out-
comes and stratified our cohort into patients who did
or did not receive FA. We therefore performed three
types of analyses: (1) the effect of a genotype on clinical
outcome inFA-untreated patients, (2) the effect of a ge-
notype on clinical outcome in FA-treated patients, (3)
the effect of FAon clinical outcomes for each genotype.METHODS
Data Collection
Patient clinical data was obtained from the Bone
Marrow Transplant Service, Department of Clinical
Haematology and the Health Information Service of
The Royal Melbourne Hospital. The patient cohort,
DNA collection, conditioning regimen, and definition
of aGVHD have been previously described [7]. The
current study included patients who received marrow
or peripheral blood stem cells from fullyHLAmatched
related donors. The original and revised Seattle Classi-
fication for chronic GVHD (cGVHD) was used as the
guideline for grading [8]. The grading range was 0 to 2,
with grade 0 as no cGVHD, grade 1 as limited disease
requiring nonsystemic treatment after day 1100, and
grade 2 as extensive cGVHD that required systemic
treatment after day 1100. EFS was defined by the
number of months until an occurrence of either disease
relapse or death, or the last recorded date of follow-up.
Survival time was calculated using the date of death or
the last recorded date of follow-up.
The mucositis score and duration for each patient
was evaluated daily by trained nurses in the bone
marrow transplant ward according to the OralMucositis Rating Scale, a specific index used to
measure acute oral mucositis after HSCT [8]. For
oral mucositis duration, the manifestation was re-
corded and analyzed as the total number of days that
a patient had recorded mucositis.
The maximum grade of mucositis was recorded as
a score between 0 and 4, where grade 0 indicated
normalmucosa and grade 4 represented pain, bleeding,
general ulceration, and inability to eat. The duration of
themaximumgrade ofmucositis was determined as the
number of days a patient remained at his or her maxi-
mum grade before improvement and recovery. The
number of days of opiates and total parenteral nutrition
(TPN)was recorded as the number of days a patient re-
quired daily opiates or TPN following transplantation.
The time to neutrophil recovery was determined by the
day the neutrophil count exceeded 0.5  109/L. Pa-
tients were treated with FA at the treating physician’s
discretion and received a standard dose of 10mg/m2 in-
travenously 6 hourly for 4 doses commencing 24 hours
after MTX administration.
Genotyping
MTHFR genotyping for the 677C.T and
1298A.C was performed by polymerase chain reac-
tion (PCR); restriction fragment length polymorphism
(RFLP) analysis was used to genotype theMTHFR 677
and 1298 SNPs [9]. Six samples were used to confirm
the PCR-RFLP results by sequencing for the geno-
types of the MTHFR 677C.T and 1298A.C SNPs.
A total of 135 of 140 and 134 of 140 unambiguous
patient genotypes were available for the MTHFR 677
and 1298 SNPs, respectively. Unambiguous typing
of 137 of 140 and 135 of 140 donor MTHFR 677 and
1298 respective genotypes was available.
Statistical Analysis
Event time distributions for the clinical outcomes
were estimated using Kaplan-Meier incidence curves.
Log-rank and univariate Cox regression tests were
used to evaluate differences in risk of an event occurring
in comparison to the expected risk for inclusion inmul-
tivariate analysis. Each predictor variablewas examined
bymeans of univariate analysis and those with a P value
\.05 were considered statistically significant. P values
between genotypes were calculated in univariate and
multivariate analyses comparatively as one genotype
versus the remaining two genotypes, against predictor
variables. All significant predictor variables, and those
withP\.25,were included in the initialCox regression
model by means of manual stepwise regression. Trend
was analyzed by anonparametric test of trend across the
ranks of across ordered groups. Demographic variables
included age, weight, disease, and gender of patient
and donor. Treatment variables included matching
status (all the patients and donors are HLA matched
724 Biol Blood Marrow Transplant 18:722-730, 2012N. M. Murphy et al.according to methods) conditioning regimen, use of
prophylactic corticosteroids, parenteral chemotherapy
within 3 months of transplantation, total MTX dose
over 11 days (mg/kg of bodyweight), nonmyeloablative
versus myeloablative transplantation, donor bone
marrow versus peripheral blood, and risk status of the
disease: standard or advanced. Data were analyzed
using Stata 8.0 software.RESULTS
Demographics andMTHFR 677C.Tand
1298A.C Genotype Frequencies
Patient demographics in the study were previously
described [7]. Patients were stratified into groups who
had or had not received FA and by the MTHFR 677
and 1298 genotypes (Supplementary Tables 1 and 2).
There were no significant differences between allele
or genotype frequencies in the donors or recipients
compared with the normal population. Genotypes
were in Hardy-Weinberg equilibrium in all three
groups [7] (Supplementary Table 3). For each multi-
variate analysis, the adjustors for the final model are
described (Supplementary Table 4).
DonorMTHFR 677C.T
GVHD outcomes for donor 677C.T
We previously reported that a patient’s first mani-
festation of GVHD occurred earlier and at a higher in-
cidence from donors with the 677CC genotype [7].
Patients not given FA who received a transplant
from a donor with the 677CC genotype were signifi-
cantly associated with earlier GVHD (incidence
93.9% versus 74.2%;mean days until GVHD62.7 ver-
sus 97.5; hazard ratio [HR] for genotype 5 2.29; 95%
confidence interval [CI], 1.31-3.99; P 5 .003)
(Figure 1A and C). The association was confirmed by
multivariate analysis (HR for genotype 5 3.16; 95%
CI, 1.72-5.82; P\ .001). There was no corresponding
association for the timing of the first manifestation of
GVHD to the donor 677 genotypes in patients given
FA (Figure 1B).
Increasingly severe aGVHD was observed in
patients not given FA who received a transplant from
a donor with the 677CC genotype (66.6% with
aGVHD grade 2-4 versus 35.5%; odds ratio [OR]
for genotype 5 3.23; 95% CI, 1.25-8.33; P 5 .02).
Accordingly, in patients not given FA, the donor
677CT genotype was significantly associated with
less severe grades of aGVHD (32.0% with aGVHD
grade 2-4 versus 64.1%; OR for genotype 5 0.24;
95% CI, 0.09-0.66; P 5 .006) (Figure 1A). Multivari-
ate analysis on the severity of aGVHD grade con-
firmed the association with the donor 677 CT
genotype (OR 5 0.29; 95% CI, 0.10-0.82; P 5 .02).Survival outcomes for donor 677C.T
Patients given FA had significantly increased sur-
vival when receiving a transplant from a donor with
the 677CCgenotype (66.6% versus 50.0%; for patients
who died, 530 days versus 208 days;HR for genotype5
0.44; 95%CI, 0.21-0.92;P5 .03) (Figure 1D). This as-
sociation was confirmed by multivariate analysis
(HR5 0.40; 95%CI, 0.19-0.87; P5 .02). An examina-
tion of the effect that FA administration had on survival
for the donor genotypes indicated a significant associa-
tion in patients receiving a transplant fromadonorwith
the 677CT genotype with decreased survival (inci-
dence change with FA, 47.8% versus 84.0%; 221 days
versus 430 days; HR for FA 5 3.53; 95% CI, 1.24-
10.03; P 5 .02) (Figure 1D). The multivariate model
confirmed this association with the donor 677CT
genotype for the use of FA, which was the only factor
remaining in the model.
Neutrophil recovery for donor 677C.T
In the donorMTHFR 677CC genotype group, FA
was significantly associated withmore rapid neutrophil
recovery (15.7 days versus 18.1 days, HR5 1.72; 95%
CI, 1.01-2.96; P 5 .05) relative to the CT and TT
genotypes (Figure 1B). This association was confirmed
by multivariate analysis (HR 5 2.30; 95% CI, 1.30-
4.05; P 5 .004).Patient MTHFR 677C.T
First observable GVHD for patient 677C.T
Wepreviously reported the lack of significant asso-
ciations in univariate andmultivariate analysis between
the timing of a first manifestation of GVHD and the
patient’sMTHFR 677CC genotype [7]. A similar anal-
ysis was performed following the stratification of the
cohort into FA-treated and -untreated groups
(Figure 2A and C). For FA-treated patients, there
wereno significant associations to the timeof apatient’s
first manifestation of GVHD with the 677 genotypes
(Figure 2B). There was a significant association
between patients with the 677CC genotype not given
FA and earlier GVHD (incidence 96.6% versus
75.0%; mean days until GVHD, 66.7 versus 89.6;
HR for genotype 5 2.07; 95% CI, 1.20-3.59; P 5
.009). This association was confirmed by multivariate
analysis (HR 5 2.22; 95% CI, 1.25-3.94; P 5 .007)
(Figure 2A).
Interactions between the donor and patient geno-
types were investigated by multivariate analysis, which
indicated the donor 677CC genotype was the signifi-
cant predictor of the time to first GVHD (HR 5
2.22; 95% CI, 1.25-3.87; P 5 .006). The other factors
remaining in themodelwere the conditioning regimens
of busulphan and cyclophosphamide (HR5 2.31; 95%
CI, 1.49-7.64; P 5 .003) and cyclophosphamide with
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Figure 1. The hazard/odds ratio of clinical outcomes influenced by the donor MTHFR 677 genotypes. (A) Patients not provided with FA rescue; (B)
patients provided with FA rescue; (C) Kaplan-Meier graph of the first day that a manifestation of GVHD was observed; (D) Kaplan-Meier graph of the
incidence of survival following transplantation. Significant associations are indicated by the hazard/odds ratio and its respective confidence interval both
\1 for a lower risk of events occurring or .1 for a higher risk of events occurring.
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P5 .02).
GVHD grade for patient 677C.T
Examining the effect of genotype on the maximum
grade of aGVHD, patients with the MTHFR 677CC
genotype not given FA were significantly associated
withmore severe aGVHD (63.3%with aGVHDgrade
2-4 versus 38.9%; OR for genotype 5 2.51; 95% CI,
1.01-6.21; P 5 .05). Correspondingly, in patients not
given FA, patients with the 677CT genotype were sig-
nificantly associated with lower grades of aGVHD
(33.3% with aGVHD grade 2-4 versus 61.5%; OR
for genotype 5 0.27; 95% CI, 0.51-0.71; P 5 .008),
which was confirmed by multivariate analysis (OR
for genotype 5 0.12; 95% CI, 0.04-0.36; P\ .001).
There were no significant associations between the
grade of cGVHD and the patient MTHFR 677 geno-
type in either the FA-treated or -untreated group.
Interactions between the donor and patient genotypes
were determined, indicating the patient 677CC geno-
type was the significant predictor of the severity of
aGVHD (identical to the aforementioned model).Survival outcomes for patient 677C.T
Examining the effect that genotypes had on sur-
vival, there were no patient MTHFR 677 genotypes
that were significantly associatedwith survival duration
and incidence (in both univariate andmultivariate anal-
ysis) in either the FA-treated or -untreated group. The
use of FA, however, was significantly associated with
decreased survival in patients with the 677CT geno-
type (incidence change with FA, 57.1% versus 85.2%;
for patients who died, 337.2 days versus 630.8 days;
HR for FA 5 3.50; 95% CI, 1.13–10.89; P 5 .02)
(Figure 2D). This finding was confirmed by multivari-
ate analysis (HR5 4.80; 95%CI, 1.49-15.5; P5 .008).EFS for patient 677C.T
There were no patient MTHFR genotypes signifi-
cantly associated with EFS in patients given or not
given FA. However, the use of FA was significantly as-
sociated with decreased EFS in patients with the
677CT genotype (incidence change with FA 53.6%
versus 18.5%; 7.3 months versus 13.7 months; HR
for FA 5 3.67; 95% CI, 1.32-10.15; P 5 .01). This
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Figure 2. The hazard/odds ratio of clinical outcomes influenced by the patient MTHFR 677 genotypes. (A) Patients not provided with FA rescue; (B)
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726 Biol Blood Marrow Transplant 18:722-730, 2012N. M. Murphy et al.association was also significant in multivariate analysis
(HR for FA 5 4.44; 95% CI, 1.55-12.8; P 5 .006).
Further observations for recipient 677C.T
The duration of oropharyngeal mucositis in
patients was significantly increased with the MTHFR
677CT in patients given FA (mean duration 17.5
days versus 11.1 days; HR 5 3.33; 95% CI, 1.79-
6.25; P\ .001). This finding was confirmed by multi-
variate analysis (HR 5 2.17; 95% CI, 1.05-4.48;
P 5 .04), with the other factor in the model being
the conditioning regimen of fludarabine with cyclo-
phosphamide (HR 5 7.82; 95% CI, 2.96-20.7; P\
.001). There were no further genotypic associations
between the MTHFR 677 genotypes in either FA-
treated or -untreated patients with mucositis related
outcomes, the days of opiates, total parenteral nutri-
tion, or the neutrophil recovery day (Figure 2A and B).
DonorMTHFR 1298 A.C
GVHD outcomes for donor 1298A.C
The donor MTHFR 1298A.C genotypes were
stratified into patients who did or did not receive FA,and assessed for associations with clinical outcomes.
There were no significant associations between the do-
nor MTHFR 1298 genotypes with the day of the first
manifestation of GVHD, the maximum grades of
aGVHD, or cGVHD in patients with or without FA
(Figure 3A, B).
Survival outcomes for donor 1298A.C
In the analysis of donor MTHFR 1298 genotypes
on survival, there was a significant decrease in survival
found with the donor 1298AA genotype in patients not
given FA (incidence 58.1% survival versus 87.9%;
for patients who died, 1082.9 versus 894.4; HR for
genotype 5 3.54; 95% CI, 1.15 10.93; P 5 .03)
(Figure 3D). This association was confirmed by multi-
variate analysis (HR for genotype 5 4.67; 95% CI,
1.32-16.48; P 5 .02).
EFS for donor 1298A.C
In patients not given FA, transplants from a donor
with the 1298AC genotype were significantly associ-
ated with increased EFS (incidence of events, 8.0%
versus 46.3%; mean time to events 2.6 months
versus 13.6 months, HR for genotype 5 0.16; 95%
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Figure 3. The hazard/odds ratio of clinical outcomes influenced by the donor MTHFR 1298 genotypes. (A) Patients not provided with FA rescue; (B)
patients provided with FA rescue; (C) Kaplan-Meier plot of EFS; (D) Kaplan-Meier plot of overall survival following transplantation. Significant associ-
ations are indicated by the hazard/odds ratio and its respective confidence interval both\1 for a lower risk of events occurring or.1 for a higher risk of
events occurring.
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was confirmed in the multivariate analysis (HR for
genotype 5 0.11; 95% CI, 0.02-0.88; P 5 .04). The
use of FA was significantly associated with reduced
event-free survival in donors with the MTHFR
1298AC genotype (hazard ratio for FA, 7.11, 95%
CI, 1.62-31.4; P 5 0.009). This association was con-
firmed by multivariate analysis (hazard ratio for FA,
6.64, 95% CI, 1.50-29.4; P 5 0.01), the other factor
influencing the model being an advanced disease state
at the time of transplant (hazard ratio, 3.80; 95% CI,
1.19-12.13; P 5 0.02).
Opiate use for donor MTHFR 1298A.C
For the analysis of the duration of opiate therapy in
the weeks following transplantation, in FA-untreated
patients, there was an association with the donor
MTHFR 1298AC genotype and decreased duration
of opiates (HR for genotype 5 0.34; 95% CI, 0.15-
0.76; P 5 .009). This association was not confirmed
by multivariate analysis. In patients given FA, the
donor 1298AC genotype was associated with a signifi-
cantly increased duration of opiate therapy (HR forgenotype 5 1.92; 95% CI, 1.06-3.45; P 5 .03) and
the donor 1298AA genotype associated with decreased
duration of opiates following transplantation (HR for
genotype 5 0.56; 95% CI, 0.32-1.00; P5 .05). Multi-
variate analysis confirmed the association of the
1299AC genotype with increased opiate therapy
(HR 5 1.89; 95% CI, 1.05-3.44; P 5 .04). We there-
fore tested FA use in transplants from a 1298AC donor,
indicating that FA use was significantly associated with
an increased duration of opiate therapy (HR for FA 5
4.76; 95% CI, 1.85-11.1; P5 .001) (Figure 3A and B),
which was confirmed by multivariate analysis (HR for
genotype 5 3.85; 95% CI, 1.56-10.0; P 5 .003).
PatientMTHFR 1298A.C
GVHD, survival, and EFS outcomes for patient
1298A.C
Patient genotype at MTHFR 1298 was also as-
sessed for associations with clinical outcomes and
stratified for those who did or did not receive FA.
There were no significant associations between any
GVHD or survival-related clinical outcomes.
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Figure 4. The hazard/odds ratio of clinical outcomes influenced by the patientMTHFR 1298 genotypes. (A) Patients not provided with FA rescue; (B)
patients provided with FA rescue; (C) Kaplan-Meier graph of the incidence of opiate use; (D) Kaplan-Meier plot of the incidence of total parenteral
nutrition use. Significant associations are indicated by the hazard/odds ratio and its respective confidence interval both\1 for a lower risk of events
occurring or .1 for a higher risk of events occurring.
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1298A.C
Therewas a significant associationwith a decreased
duration of total parenteral nutrition in patients with
the MTHFR 1298AC genotype not given FA (HR 5
2.22; 95% CI, 1.11–4.33; P 5 .02) (Figure 4A and D).
Multivariate analysis revealed the patient 1298AC
genotype as the only factor remaining in the model.
Opiate use for patient MTHFR 1298A.C
Patients with the MTHFR 1298AC genotype who
were not given FA had a decreased duration of opiate
use posttransplantation (HR for genotype 5 0.39;
95% CI, 0.18-0.87; P 5 .02) (Figure 4A and C). This
association was confirmed by multivariate analysis
(HR 5 0.42; 95% CI, 0.19-0.95; P 5 .04).
For patients with the 1298AC genotype, the use of
FAwas significantly associated with increased duration
of opiate use posttransplantation (HR5 3.45; 95%CI,
1.43-8.33; P5 .006) (Figure 4B). This association was
confirmed by multivariate analysis (HR 5 7.69; 95%CI, 2.38-25.0; P 5 .001), with the other factor in the
model being a myeloablative rather than a reduced-
intensity conditioning regimen (HR 5 0.11; 95% CI,
0.03-0.47; P 5 .002).DISCUSSION
In this retrospective study, numerous associations
were found relating patient and donorMTHFR geno-
types that influenced GVHD, survival, EFS, and opi-
ate use. Stratifying the study into patients who did or
did not receive FA revealed a differential association
between the SNPs and clinical associations.
In patients without FA, earlier and more severe
GVHD was observed with the 677C SNP in both do-
nor and patient genotypes, with the association being
abrogated by FA. As no similar association was found
with the MTHFR 1298 genotypes with the timing
or severity of GVHD, we hypothesize that these
results reflect the decreased metabolic activity with
MTHFR 677T mutation [10]. During HSCT, MTX
Biol Blood Marrow Transplant 18:722-730, 2012 729Effect of Folinic Acid on MTHFRadministration limits donor T-lymphocyte prolifera-
tion by binding to the enzyme dihydrofolate reductase
(DHFR) [11], and folate cycle blockade continues
until clearance of MTX [12]. De novo folate metabo-
lism is blocked from folate derived from 5,10-
methylenetetrahydrofolate, not FA rescue in cases of
MTX toxicity [13], resulting in the arrest of thymidine
and cellular methylation (ie, alloreactive T-lympho-
cytes and neoplastic cells progressing through the
G2/S-phase), and are presumed to undergo apoptosis
because of the lack of thymidine available forDNAsyn-
thesis. The provision of FA abrogates the genotypic as-
sociation by circumventing the effect of the MTX
blockade, bypassing the relatively decreased metabolic
potential of theMTHFR 677T SNP.Without FA sup-
plementation, the decreased folate supply with the
677T variant may inhibit the supply of folate required
to activate T-lymphocytes into a mature population
able to elicit a GVHD response. Previous studies
have demonstrated in lymphocytes that the MTHFR
677T variant showed increased sensitivity to MTX
in vitro [14] and a propensity for the variant to be asso-
ciated with hypomethylation [15], which offer alterna-
tive explanations for the mechanism of action.
The association between both reduced survival and
EFS to the donor MTHFR 1298AA genotype in
FA-untreated patients is in contrast to the lack of asso-
ciation in FA-treated patients. One possible explana-
tion is based on the metabolism of folate by MTHFR
for nucleic acid synthesis, which also provides a methyl
group for methylation reactions. Following HSCT,
the cessation of MTX and subsequent resumption of
folate distribution potentially amplifies the role of
MTHFR [16] and accordingly, the effect of each
SNP. It has been suggested there is significantly
decreased genomic DNA methylation in lymphocytes
with the MTHFR 1298AA genotype, when compared
with the AC and CC genotypes [17]. This relatively
decreased cellular methylation may be contributing
to increased relapse and mortality, because of reduced
methylation of the donor CD341 cells and inhibited
development into a stable graft. Both the donor and pa-
tientMTHFR 1298AC genotypes were associated with
decreased duration of opiates in the absence of FA, the
effect of which was reversed in the donor with FA ad-
ministration. Accordingly, patients with the MTHFR
1298AC genotype had a decreased duration of total
parenteral nutrition, despite similar incidents of muco-
sal injury. Each of these results was predominantly ob-
served 2 weeks posttransplantation, following
cessation of MTX treatment. As folic acid is a standard
constituent of TPN, the effect may be related to the
ongoing provision of folic acid once MTX therapy is
complete. The specific impacts of constituents of
TPON solutions may require further elucidation.
There were no significant findings in either univar-
iate or multivariate analysis that supported a role forMTHFR SNPs influencing mucositis related outcomes.
However, there was a trend for patients with the
MTHFR 677CT genotype to have a longer duration of
mucositis when given FA. This result is open to inter-
pretation, but it does raise the possibility that either
patients with the MTHFR 677CT genotype do not re-
spond toFAor that the potential confounding diagnosis
of oral aGvHD was misdiagnosed as MTX toxicity.
This study found no significant associations between
the use of FA and maximum grade of mucositis, nor
the duration of the maximum grade of mucositis. How-
ever, the total duration ofmucositis in patients adminis-
tered FA was significantly greater (data not shown).
Our previous analysis used a cohort of 53 unrelated
HSCT patients in addition to the 140 described.
Univariate analysis on the 53 transplants indicated an
opposing effect of the donor MTHFR 1298AC geno-
type, with a significantly reduced patient survival
(data not shown). Because of the small numbers, a com-
plete multivariate analysis could not be performed.
This study partially supports the reporting of a de-
creased risk of disease relapse for recipients with the
MTHFR 677 CT/1298 AC genotypes in chronic
myeloid leukemia patients [18], but the study found
no overall effect on survival. This may be a result of
the differences between the cohorts in underlying
diagnoses. A separate study has shown an increase
between the recipient MTHFR 677TT genotype and
decreased survival [19]. This present study found
a similar association in patients not given FA, which
was not confirmed in multivariate analysis. Prelimi-
nary bivariate analysis on the association between the
MTHFR 1298AA genotype in non-FA-treated patients
indicated the genotypic effect remained, with the stem
cell dosage also being significant.
In conclusion, we confirm the previously reported
associations betweenMTHFR 677 and 1298 SNPs and
patient outcomes after HSCT and describe new asso-
ciations regarding overall survival. Second, we have
provided evidence of differential effects of MTHFR
SNPs in metabolizing folate derivatives posttransplan-
tation. Third, we suggest that including the results of
MTHFR genotypes in donor selection algorithms
could provide a novel method for improving patient
outcomes. Finally, we have raised the possibility of
folate and folinic acid impacting on clinical outcomes
other than MTX-induced toxicities.
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